Om

Liminatus Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies with an emphasis on immuno-oncology approaches. The company concentrates on immune-modulating treatments designed to target tumors more precisely by harnessing the body’s own immune system. Liminatus Pharma’s lead work includes a Guanylyl Cyclase C (GCC)–targeted vaccine being evaluated in mid-stage clinical trials for colorectal, pancreatic, gastric, and esophageal cancers that express GCC, addressing tumor types with significant unmet medical need. Its programs are positioned within the broader biotechnology and healthcare sectors, contributing to the oncology treatment landscape through novel therapeutic platforms rather than traditional chemotherapies. Liminatus Pharma Inc. operates today as a specialized innovator in cancer drug development, engaging primarily in research, clinical testing, and related translational activities. Founded in 2020 and headquartered in Cerritos, California, the company plays a focused role in the market as an emerging developer of targeted immuno-oncology candidates.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I LIMINATUS PHARMA MED ENDAVU: Køb Liminatus Pharma ($LIMN) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Liminatus Pharma, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.